IDH1 and central nervous system cancer: IDH mutation, recognized as an important marker for the classification and prognosis of glioma, would lead to production of the oncometabolite D-2- hydroxyglutarate and might reprogram the metabolism (Yan et al., 2009; Pirozzi and Yan, 2021).